BRS201 (hydroxocobalamin)

BRS201 is a clinical code for hydroxocobalamin, the same vitamin B12 form hospitals use to treat cyanide poisoning, repositioned as a chemical sponge for hydrogen sulfide gas (H2S) in the colon. A Phase 2 investigator-initiated trial at Brigham and Women's Hospital (NCT06420375) [1] is testing whether scavenging H2S, which is overproduced by certain gut bacteria in ulcerative colitis (UC) patients, can dent the disease. The trial is small (n=20), academically sponsored, uses oral hydroxocobalamin plus oral butyrate with a one-time IV loading dose, and is built around a biochemical endpoint rather than clinical remission. There is no public commercial developer, no FDA designation, and no clear path from this study to a marketed UC therapy without an outside licensee picking up the program.

Hydroxocobalamin itself is not a new molecule. It is FDA-approved as Cyanokit (Meridian Medical Technologies, NDA 022041, 2006) for known or suspected cyanide poisoning [2], with decades of human safety data at very high IV doses (5g infusions). The 'BRS201' designation appears to be an internal study code used by the Brigham and Women's group, not a commercial development name, and no public company has claimed the asset. No FDA breakthrough therapy, fast track, orphan drug, or accelerated approval designation applies to the UC indication. The current Phase 2 study (NCT06420375) [1] is open and recruiting with a 20-patient target, primary endpoint being a pharmacodynamic biomarker (a lab readout showing the drug is hitting its intended target - here, reduction of plasma H2S metabolites - as distinct from showing the patient is getting better), not Mayo score or mucosal healing. A parallel acute-colitis study (NCT06420492, n=20) [3] and a primary sclerosing cholangitis (PSC, a chronic bile duct disease that occurs in roughly 5% of UC patients and shares hypothesized microbial drivers) study (NCT05835505, n=28) [4] from the same group suggest a broader H2S-disease platform. Without a corporate sponsor, there is no NDA supplement timeline.

Hydroxocobalamin is vitamin B12 with a hydroxyl group on the cobalt center. That cobalt has high affinity for cyanide, where cyanide displaces the hydroxyl ligand to form cyanocobalamin (the basis of Cyanokit), and has separate, less well-characterized binding chemistry with hydrogen sulfide. H2S is a noxious gas produced in the colon by sulfate-reducing bacteria, especially Desulfovibrio species, which have been reported to be enriched in UC patients [5]. The disease biology link: H2S poisons mitochondria in colonocytes, the cells lining the colon, specifically blocking their ability to burn butyrate, a short-chain fatty acid that is their main fuel. Starve the colonocytes of energy, and the gut barrier breaks down, letting bacteria provoke inflammation. This 'energy deficiency' theory of UC traces back to Roediger's 1980 Lancet paper [6]. The cobalt-H2S binding has been demonstrated in vitro, but whether oral hydroxocobalamin scavenges H2S fast enough and in sufficient quantities to meaningfully lower colonic H2S in an inflamed colon is unproven, and is precisely the bet this trial is testing. Researchers have questioned whether the binding kinetics and stoichiometry support a real pharmacodynamic effect in vivo. Mechanism rationale is defensible, clinical validation is essentially absent.

NCT06420375 is a Phase 2, single-center, randomized, placebo-controlled crossover study at Brigham and Women's Hospital, enrollment target 20 mild UC patients, currently recruiting [1]. Per the registry and trial-listing summaries, the regimen is oral hydroxocobalamin at 1.2g once or twice daily combined with oral butyrate 120mg twice daily for 4 weeks, with a one-time 2.5g IV hydroxocobalamin loading dose at initiation [1][8]. Primary endpoint is reduction of H2S metabolites in plasma, a pharmacodynamic biomarker. Secondary endpoints include fecal calprotectin (a stool protein elevated when the gut lining is inflamed, used as a non-invasive surrogate for disease activity) and partial Mayo score (a standardized clinical scoring system rating UC severity based on stool frequency, rectal bleeding, and physician global assessment; the full Mayo score also includes endoscopic findings). There is no active comparator. The companion study NCT06420492 (n=20) [3] tests the same compound in acute colitis with sulfur metabolism as the primary readout. This is a proof-of-mechanism design typical for academic translational work: small, biomarker-driven, no comparator, intended to answer 'does the drug hit its pharmacology in patients' before anyone commits to a real efficacy trial. A clean positive biomarker signal would justify a properly powered Phase 2b with full Mayo scores or endoscopic remission (visible healing of the inflamed colon lining on colonoscopy, a stricter endpoint than symptom relief). A miss kills the program. The n=20 sample size cannot support meaningful safety inference beyond gross adverse-event spotting, though hydroxocobalamin's prior safety database substantially mitigates that gap. The oral route raises a second pharmacology question: standard oral cobalamin has very low systemic bioavailability and the colon-delivery characteristics of this regimen, beyond co-administration with butyrate, are not described in the public registry.

Our model puts this drug's approval odds at 3%. That starts from a historical baseline of about 23% for Phase 2 drugs in this area, then adjusts based on ten specific facts about the trial and its sponsor. The estimate is pulled down mainly by heavier-than-usual blinding, a thin sponsor approval record, weak earlier-phase results, and smaller-than-typical enrollment. The remaining factors are close to average for this stage, so they leave the number roughly where the baseline set it.

Efficacy risk dominates. The H2S hypothesis in UC has been around for over 30 years without producing a successful drug, which suggests the biology is more complicated than the simple scavenger model. Plasma H2S metabolites may not track colonic H2S concentration, and lower colonic H2S may not translate into improved colonocyte function or reduced inflammation. The cobalt-H2S binding kinetics may also be too slow to compete with H2S's diffusion and metabolism in vivo, even if equilibrium binding looks favorable in vitro. The primary endpoint tells us nothing about whether patients feel better or look better on endoscopy. Pharmacology risk: oral cobalamin has very low systemic bioavailability, and while the trial includes a 2.5g IV loading dose, sustained colonic H2S scavenging would have to come from the oral 1.2g daily or twice-daily regimen, which is the part the registry does not fully justify. Safety risk is low given hydroxocobalamin's history at much higher IV doses than the daily oral exposure here. Execution risk is real: single-site, n=20, academic recruiting pace, with the related NCT06420492 trial competing for the same patient pool. The most severe issue is commercial. With no corporate sponsor, off-patent generic status for the parent compound, and no obvious method-of-use or formulation IP disclosure visible in public databases, a positive readout most likely produces a published paper, not a product. Any future commercialization needs a startup willing to file new-formulation or new-use IP and run a real Phase 2b. The investigators have a related earlier protocol on hydroxocobalamin plus butyrate in UC remission (NCT04259060) [8], which is the most direct precedent and bears watching for any prior pilot results.

Watch this for the science, not the stock. BRS201 is a mechanistic probe asking whether H2S scavenging does anything measurable in UC patients. A positive H2S-reduction signal in 2026 or 2027 would be interesting target validation and might pull a startup or small biotech toward a colon-targeted hydroxocobalamin formulation or a more potent next-generation H2S binder. A clean negative result would close a long-running UC hypothesis. Neither outcome moves a public stock today, because no public company owns this program. The data point to watch: paired biomarker reduction plus directional clinical signal (partial Mayo subscore, fecal calprotectin) in the eventual peer-reviewed report. Expected readout late 2026 to 2027. For commercial context, any future BRS201-derived therapy would compete in a crowded UC market against approved standards of care including the anti-integrin biologic vedolizumab, the anti-IL-12/23 biologic ustekinumab, the S1P modulator ozanimod, and the JAK inhibitor upadacitinib. These are not mechanistic competitors but are the clinical bar a new mechanism must clear or complement. The interesting investable angle is not BRS201 itself but the broader microbiome-and-metabolite UC space. Seres Therapeutics' SER-287, a donor-derived bacterial consortium, failed its Phase 2b ECO-RESET trial in mild-to-moderate UC in 2021 [9], illustrating how clean microbiome theses have not yet produced approved UC drugs. Vedanta Biosciences' VE202 is a defined-consortium program with IBD-relevant clinical work and is the closer parallel for what a defined-mechanism microbial-axis UC asset looks like commercially. (Finch Therapeutics is sometimes grouped with this space, but Finch's lead program was C. difficile, not UC, and Finch wound down operations and divested assets in 2023.) The Brigham group's parallel H2S work in PSC (NCT05835505) and acute colitis (NCT06420492) is worth tracking as a coordinated translational thesis. Treat the academic-sponsor field as a known data caveat: Brigham and Women's Hospital is the trial sponsor of record, but the underlying drug developer is not publicly disclosed.